These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29314630)

  • 1. Fibrin fuels fatty liver disease.
    Lisman T; Jenne CN
    J Thromb Haemost; 2018 Jan; 16(1):3-5. PubMed ID: 29314630
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
    Wang XC; Gusdon AM; Liu H; Qu S
    World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
    Gastaldelli A
    Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADV36 adipogenic adenovirus in human liver disease.
    Trovato FM; Catalano D; Garozzo A; Martines GF; Pirri C; Trovato GM
    World J Gastroenterol; 2014 Oct; 20(40):14706-16. PubMed ID: 25356033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing liver fibrosis in patients with NAFLD and the road ahead.
    Nobili V; Miele L; Alisi A
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
    [No Abstract]   [Full Text] [Related]  

  • 6. Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.
    Lallukka S; Luukkonen PK; Zhou Y; Isokuortti E; Leivonen M; Juuti A; Hakkarainen A; Orho-Melander M; Lundbom N; Olkkonen VM; Lassila R; Yki-Järvinen H
    Thromb Haemost; 2017 Jan; 117(2):286-294. PubMed ID: 27929200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
    Athyros VG; Katsiki N; Doumas M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
    [No Abstract]   [Full Text] [Related]  

  • 8. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
    Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation.
    Drabik L; Wołkow P; Undas A
    Stroke; 2017 Oct; 48(10):2716-2722. PubMed ID: 28904234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease.
    Azzu V; Vacca M; Virtue S; Allison M; Vidal-Puig A
    Gastroenterology; 2020 May; 158(7):1899-1912. PubMed ID: 32061598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prevalence of Elevated Alanine Aminotransferase Levels Meeting Clinical Action Thresholds in Children with Obesity in Primary Care Practice.
    Wu SJ; Darbinian JA; Schwimmer JB; Yu EL; Ramalingam ND; Greenspan LC; Lo JC
    J Pediatr; 2022 Jan; 240():280-283. PubMed ID: 34562443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.
    Panera N; Della Corte C; Crudele A; Stronati L; Nobili V; Alisi A
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):393-403. PubMed ID: 26654761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.
    Samuelson Bannow BT; Lee A; Khorana AA; Zwicker JI; Noble S; Ay C; Carrier M
    J Thromb Haemost; 2018 Jun; 16(6):1246-1249. PubMed ID: 29737593
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.